November 16, 2020 -- Clover Biopharmaceuticals is working with Cytiva to scale up the company's COVID-19 vaccine manufacturing capabilities.
The partnership will help to accelerate the development and manufacturing of Clover's protein-based S-Trimer subunit vaccine candidate. The candidate showed promising preliminary results in a phase I clinical study, according to the company.
Clover upstream current good manufacturing practice manufacturing site in Zhejiang, China. Image courtesy of Cytiva.
Clover aims to expand the Cytivia FlexFactory capacity from 2 x 2,000 L to 4 x 2,000 L with the addition of two 2,000-L bioreactors. The factory will process equipment, services, and consumables for vaccine development in order to meet Clover's phase II/III clinical production plan as well as to reach commercial readiness should a vaccine be approved.
Copyright © 2020 scienceboard.net